Superworth

Pacific Biosciences of California price to book ratio PACB

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
184×
Jul 2026
10-year median
5.0×
10-year range
0.5× to 196×
Peer median
6.7×

Pacific Biosciences of California's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Jul 2026, at 184×.

On the days it had one over the last ten years, its median was 5.0×, from 0.5× in Jul 2024 to 196× in May 2026.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far184×13.5×196×
202514.8×0.6×20.0×
20241.1×0.5×3.3×
20233.4×2.3×5.1×
20223.0×1.3×4.4×
20215.4×5.4×70.0×
202036.1×7.4×53.6×
201915.7×7.7×16.6×
20188.3×2.8×11.7×
20173.0×3.0×5.7×
20163.6×3.6×23.9×
201524.5×7.6×24.7×
201410.5×3.9×10.5×
20134.1×0.8×4.1×
20120.7×0.5×1.3×
20110.7×0.6×1.4×

Against its peers

Companies in Medical - Diagnostics & Research nearest Pacific Biosciences of California's size, closest first, today.

CompanyPrice to book ratio
PACBPacific Biosciences of Californian/m
NRCNRC Health74.1×
CDNACareDx8.4×
VCYTVeracyte2.8×
ICCCImmucell3.0×
BLLNBillionToOne9.5×
LNTHLantheus5.0×
Peer median6.7×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Pacific Biosciences of California

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.